| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/09/2002 | EP1169317A1 Triarylimidazoles |
| 01/09/2002 | EP1169313A2 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
| 01/09/2002 | EP1169312A2 Glucokinase activators |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169056A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169047A1 Compositions and methods for treatment of diabetes |
| 01/09/2002 | EP1169045A2 Immunomodulating polymers |
| 01/09/2002 | EP1169043A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones |
| 01/09/2002 | EP1169025A2 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 01/09/2002 | EP1168935A1 Cacao extract including dietary fiber |
| 01/09/2002 | EP1168934A1 Hydrogel-forming system with hydrophobic and hydrophilic components |
| 01/09/2002 | EP0984699A4 Method of inhibiting immune system destruction of transplanted viable cells |
| 01/09/2002 | EP0789764B1 A novel family of protease inhibitors, and other biologic active substances |
| 01/09/2002 | CN1330660A Cycle tetrapeptide compound and their use |
| 01/09/2002 | CN1330655A Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| 01/09/2002 | CN1330652A 2,3,4,4-tetrahydro-1H-pyrazino (1,2-a) quinoxalin-5(6H) one deivatives being 5HT2C agonists |
| 01/09/2002 | CN1330650A Dibenz [a.g] quinolizinium derivatives and salts thereof |
| 01/09/2002 | CN1330641A Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidzole-5-carboxamide |
| 01/09/2002 | CN1330636A Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5HT1A receptor activity |
| 01/09/2002 | CN1330548A Phospholipid complexes of proanthocyanidin A2 used as antiatherosclerotic agents |
| 01/09/2002 | CN1330544A Combination of cerivastatin and fibrates |
| 01/09/2002 | CN1330538A Stable pharmaceutical formulation comprising HMC-CoA reductase inhibitor |
| 01/09/2002 | CN1329922A Join of C peptide and insulin for treating diabetes complication and C peptide-specific antibody |
| 01/09/2002 | CN1329917A Medicine for treating Type-2 diabetes and its preparing process |
| 01/09/2002 | CN1329911A Health-care medicinal liquor |
| 01/09/2002 | CN1329904A Process for preparing arnebia root medicine with broad-spectrum medical functions |
| 01/09/2002 | CN1329893A Chinese medicine for decreasing fat and lossing weight and preparation method thereof |
| 01/09/2002 | CN1329888A Method for preparing medicine containing substitution pyridyl dihydric heptene acid or it salt |
| 01/08/2002 | US6337349 Stable and nonhygroscopic salts to form tablets, capsules, powders, etc. suitable for dietary/nutritional humans supplements and a feed supplement for veterinary medicine; high-energy metabolism; cardiovascular systems |
| 01/08/2002 | US6337327 Drugs for enzyme inhibiting such as angiotensin converting enzyme |
| 01/08/2002 | US6337325 Combined preparation for the therapy of immune diseases |
| 01/08/2002 | US6337076 Applying onto hypertrophic scar a liquid formulation comprising collodion film-forming carrier having dermatologically effective amount of active ingredient capable of reducing size of scar or improving appearance |
| 01/08/2002 | US6337075 Methods for treating diabetes |
| 01/08/2002 | US6337048 Useful for increasing the solubility and dispersibility of consumer products such as food products, botanicals, medical products, involves applying continuos stream of oxygen containing gas to a material in a sealed chamber |
| 01/08/2002 | CA2205202C Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| 01/08/2002 | CA2161805C An exercise hydration regimen to enhance exercise endurance and performance |
| 01/08/2002 | CA2143263C Orally administrable raloxifene formulations |
| 01/03/2002 | WO2002000873A1 Human site-1 protease promoter |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000730A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000725A2 G-protein coupled receptor org10 |
| 01/03/2002 | WO2002000710A2 B7-like molecules and uses thereof |
| 01/03/2002 | WO2002000692A2 Pd-l2 molecules: pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000674A1 Phosphoglycan messengers and their medical uses |
| 01/03/2002 | WO2002000673A1 Phosphoglycan messengers and their medical uses |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000654A1 Melanocortin receptor ligands |
| 01/03/2002 | WO2002000633A1 Quinolinyl and benzothiazolyl ppar-gamma modulators |
| 01/03/2002 | WO2002000612A1 Glucagon antagonists/inverse agonists |
| 01/03/2002 | WO2002000611A2 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | WO2002000254A2 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 01/03/2002 | WO2002000223A1 Use of potassium channel agonists for reducing fat food comsumption |
| 01/03/2002 | WO2002000222A1 Use of potassium channel agonists for the treatment of cancer |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000212A1 Controlled release arginine formulations |
| 01/03/2002 | WO2002000207A1 The controlled release preparation of insulin and its method |
| 01/03/2002 | WO2002000204A1 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000042A2 Compositions and methods for body weight management |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001045695A3 Calcium formate for use as a phosphorus binder and a dietary supplement |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | WO2001044260A3 Novel purines |
| 01/03/2002 | WO2001042265A3 N6 heterocyclic 8-modified adenosine derivatives |
| 01/03/2002 | WO2001028527A3 Direct compression polymer tablet core |
| 01/03/2002 | US20020002282 Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| 01/03/2002 | US20020002203 Administering an effective amount of a compound selected from aryl(and heterocyclic) ureido and aryl(heterocyclic) carboxamido phenoxyisobutyric acids as inhibitor of glycation and advanced glycation endproducts (AGEs) (protein-aging) |
| 01/03/2002 | US20020002200 Novel diphenylethylene compounds |
| 01/03/2002 | US20020002190 Antidiabetic agents increasing the expression of glucokinase (GK) to improve glucose tolerance; increase in glucose exposure coupled through GK in beta-cells to increase insulin secretion and in hepatocytes to increase glycogen deposition |
| 01/03/2002 | US20020002186 Pharmaceutical composition |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002169 Protein kinase inhibitors |
| 01/03/2002 | US20020002168 Heterocyclic carboxamides |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002161 5-HT ligands used to treat central nervous system disorders |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | US20020002135 Pharmaceutical use |
| 01/03/2002 | US20020001622 By blending redried corn starch, silica and at least one vitamin in a blender in any order to make a dry, free-flowing powder; economical method |
| 01/03/2002 | DE10030375A1 Verwendung von MTP-Inhibitoren zur Senkung von ppTRL Use of MTP inhibitors to reduce ppTRL |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2427811A1 Phosphoglycan messengers and their medical uses |
| 01/03/2002 | CA2427742A1 Phosphoglycan messengers and their medical uses |
| 01/03/2002 | CA2415873A1 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | CA2414303A1 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2414098A1 Human site-1 protease promoter |
| 01/03/2002 | CA2413816A1 Controlled release arginine formulations |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412635A1 Novel proteases |